PCV chemotherapy for recurrent glioblastoma multiforme
- 9 January 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 56 (1) , 118-120
- https://doi.org/10.1212/wnl.56.1.118
Abstract
The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status ≥ 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.Keywords
This publication has 7 references indexed in Scilit:
- Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical TrialsJournal of Clinical Oncology, 1999
- Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapyNeurology, 1998
- Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent gliomaJournal of Neuro-Oncology, 1998
- Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1994
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990
- Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomasJournal of Neurosurgery, 1985
- Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumorsCancer, 1975